Reprogramming of HEK293 for High-Yield AAVs

acib_open_innovation-pn0gwbmnm7mep6gvfoep1yj3d1ipxdg4q1xmb83d78

We offer a collaborative project that combines genome-scale metabolic modeling with targeted multi-omics analyses to optimize gene therapy manufacturing. By systematically identifying and resolving bottlenecks in HEK293 cells, we boost viral vector yield and quality - advancing scalable and efficient gene therapy solutions.

Background

Gene therapy is revolutionizing medicine, but scalable, cost-efficient manufacturing remains a major hurdle. HEK293 cells are the workhorse for viral vector production, yet yields are often low, and the ratio of full-to-empty capsids remains suboptimal. Current process improvements rely heavily on trial-and-error. While single-omics studies have shed some light on cellular behavior, an integrated, systems-level approach is still missing. A predictive, data-driven strategy could unlock major gains in vector quality and productivity – moving gene therapy closer to true industrial scalability.

Technology

Our technology combines condition-specific genome-scale metabolic modelling with multi-omics data to uncover hidden metabolic bottlenecks and regulatory nodes. This approach recently pinpointed pseudohypoxia and HIF1α signalling as key barriers in HEK293 cells – where targeted inhibition more than doubled capsid output. Beyond mapping limitations, our models guide rational strain engineering and process design, offering a powerful tool for optimizing viral vector manufacturing.

Offer

We co-develop next-generation AAV production platforms using our multi-omics integrated genome-scale metabolic modelling framework. Our expertise includes model construction, data integration, and experimental validation. By joining forces, you gain access to:
  • Tailored genome-scale metabolic modelling of proprietary or commercial HEK293 derivatives.
  • Integrated omics profiling under relevant bioprocess conditions
  • Predictive simulations to guide genetic, media, and process optimization.
  • In silico screening of intervention strategies before experimental trials to reduce lab time and save costs.

This approach accelerates the development of high-yield, high-quality AAV manufacturing systems with reduced cost of goods.

 

IP generated in a project with acib can be fully transferred. We are looking for industrial partners to co-develop HEK293-based AAV production platforms tailored to your vector design and manufacturing requirements.

Experts:

Leopold Zehetner, Jürgen Zanghellini

Development status:

Status of the project proposal – Technology Readiness Level 4 (Technology validated in lab)

Keywords:

HEK293, Metabolic Model, Metabolic Flux Analysis, Omics Integration, AAV Production, Viral Vector, Capsid Quality, Cell Line Productivity, Bioprocess, HIF1α

HEK293 Cells image by Gemini

Dr. Martin U. Trinker
Director Business Development & Fundraising
Krenngasse 37
8010 Graz
+43 316 873 9316